InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:29 August 2023

ENHANCE-3: This phase III study is trying to understand the effectiveness of immunotherapy (magrolimab) versus placebo, in combination with targeted therapy and chemotherapy (venetoclax and azacitidine) in people with newly diagnosed, previously untreated acute myeloid leukaemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Clinical summary

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Placebo Comparator Arm. In the Experimental Arm, participants will receive magrolimab + venetoclax + azacitidine. Magrolimab will be administered intravenously at a dose of 1mg/kg priming dose on Days 1 and 4; 15mg/kg on Day 8; and 30mg/kg on Days 11, 15 and then every week for 5 doses and every 2 weeks after that. Venetoclax will be administered orally at a dose of 100mg on Cycle 1 Day 1, 200mg on Cycle 1 Day 2, 400mg on Cycle 1 Day 3 and daily after that. Azacitidine will be administered either subcutaneously or intravenously, at a dose of 75mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle. Each cycle is 28 days. In the Placebo Comparator Arm, participants will receive a magrolimab placebo + venetoclax + azacitidine. Magrolimab placebo will be given intravenously on Days 1, 4, 8, 11 and 15, then every week for 5 doses and every 2 weeks after that. Venetoclax and Azacitidine will be administered the same as in the Experimental Arm.

Age

People18+

Phase

III

Trial Acronym

ENHANCE-3

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Gilead Sciences, Inc.

Scientific Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Exclusion

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

Not yet recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more